Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Apellis Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 260
- −2 vs. Q3 2024
- Shares held
- 126.7M
- +8.67M (+7.3%) vs. Q3 2024
- Total value
- $4.04B
- +$639.2M (+18.8%) vs. Q3 2024
- New holders
- 61
- 98 more added
- Sold out
- 63
- 72 more reduced
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $10.2K |
| Q1 2026 | 324 | $5.56B |
| Q4 2025 | 280 | $3.17B |
| Q3 2025 | 273 | $2.77B |
| Q2 2025 | 247 | $2.28B |
| Q1 2025 | 255 | $2.80B |
| Q4 2024 | 260 | $4.04B |
| Q3 2024 | 265 | $3.41B |
| Q2 2024 | 263 | $4.43B |
| Q1 2024 | 302 | $6.65B |
| Q4 2023 | 284 | $6.82B |
| Q3 2023 | 256 | $4.34B |
| Q2 2023 | 317 | $9.71B |
| Q1 2023 | 282 | $7.28B |
| Q4 2022 | 244 | $5.20B |
| Q3 2022 | 250 | $6.66B |
| Q2 2022 | 212 | $4.15B |
| Q1 2022 | 212 | $4.62B |
| Q4 2021 | 187 | $3.83B |
| Q3 2021 | 181 | $2.29B |
| Q2 2021 | 205 | $4.08B |
| Q1 2021 | 175 | $2.80B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Apellis Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Oconnor LLC | 0 | $0 | 0.00% | −7,603−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −7,197−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −6,522−100.0% | Sold out |
| Whittier Trust Co | 0 | $0 | 0.00% | −3,700−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −3,202−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −2,100−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −1,944−100.0% | Sold out |
| Golden State Equity Partners | 0 | $0 | 0.00% | −1,050−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −949−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −863−100.0% | Sold out |
| Gilliland Jeter Wealth Management LLC | 0 | $0 | 0.00% | −712−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −542−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −248−100.0% | Sold out |
| Ci Investments Inc. | 0 | $0 | 0.00% | −165−100.0% | Sold out |
| Rakuten Securities, Inc. | 0 | $0 | 0.00% | −159−100.0% | Sold out |
| Wolff Wiese Magana LLC | 0 | $0 | 0.00% | −147−100.0% | Sold out |
| Reuter James Wealth Management, LLC | 0 | $0 | 0.00% | −124−100.0% | Sold out |
| Whittier Trust Co of Nevada Inc | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Key Financial Inc | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| Park Place Capital Corp | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Ghost Tree Capital, LLC | – | – | – | – | Not filed |
| Raymond James & Associates | – | – | – | – | Not filed |
| Raymond James Financial Services Advisors, Inc. | – | – | – | – | Not filed |